Cargando…
Time to ‘Mind the Gap’ in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2
A pipeline of effective direct-acting antivirals (DAAs) remains a critical gap in addressing the current pandemic given vaccination hesitancy, the emergence of viral variants of concern, susceptible populations for which vaccination is ineffective or unavailable, and the possibility that coronavirus...
Autores principales: | Jonsson, Colleen B, Golden, Jennifer E, Meibohm, Bernd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238655/ https://www.ncbi.nlm.nih.gov/pubmed/34256351 http://dx.doi.org/10.1016/j.coviro.2021.06.008 |
Ejemplares similares
-
Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients
por: Meibohm, Bernd
Publicado: (2022) -
Discovery of direct-acting antiviral agents with a graphene-based fluorescent nanosensor
por: Park, Se-Jin, et al.
Publicado: (2020) -
Advances in the Development of Small Molecule Antivirals against Equine Encephalitic Viruses
por: Ogorek, Tyler J., et al.
Publicado: (2023) -
Small Molecule Antiviral Compound Collection (SMACC): a database to support the discovery of broad-spectrum antiviral drug molecules
por: Martin, Holli-Joi, et al.
Publicado: (2022) -
SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)